Download PDF
Thromb Haemost 2005; 93(03): 618-619
DOI: 10.1055/s-0037-1616561
Letters to the Editor
Schattauer GmbH

Nocturnal rise of urinary thromboxane B2 in patients with coronary artery disease

Filippo L. Fimognari
1   The Division of Internal Medicine, Asl Roma G/Parodi-Delfino Hospital, Colleferro(Rome), Italy
,
Gianfranco Piccirillo
2   The Department of Aging Science, University La Sapienza, Rome, Italy
,
Jaime Lama
3   The Division of Internal Medicine, Nacional Hipoli to Unanue Hospital, Lima, Perù
,
Paolo De Marzio
4   The Department of Internal Medicine, University La Sapienza, Rome, Italy
,
Sergio Morelli
4   The Department of Internal Medicine, University La Sapienza, Rome, Italy
,
Girolamo Monteleone
5   The Laboratory of Clinical Pathology, Asl 9/Del Balzo-Squillacioti Hospital, Locri (RC), Italy
,
Vincenzo Mollace
6   The Faculty of Pharmacy, University of Catanzaro Magna Graecia, Roccellettadi Borgia (CZ), Italy
,
Francesco Violi
7   The Division of IV Medical Clinic, University La Sapienza, Rome, Italy
› Author AffiliationsThe study was carried out in the Division of IV Medical Clinic, University La Sapienza, Rome, Italy
Further Information

Publication History

Received 28 July 2004

Accepted after resubmission 30 December 2004

Publication Date:
14 December 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Muller JE, Toefler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989; 79: 733-43.
    CrossrefPubMedGoogle Scholar
  • 2 Andreotti F, Davies GJ, Hackett DR et al. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death, and stroke. Am J Cardiol 1988; 62: 635-7.
    CrossrefPubMedGoogle Scholar
  • 3 Willich SN, Pohjola-Sintonen S, Bhatia SJS et al. Suppression of silent ischemia by metoprolol without alteration of morning increase of platelet aggregability in patients with stable coronary artery disease. Circulation 1987; 76: 488-91.
    CrossrefPubMedGoogle Scholar
  • 4 Tofler GH, Brezinski DA, Schafer A et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden death. N Engl J Med 1987; 316: 1514-8.
    CrossrefPubMedGoogle Scholar
  • 5 Brezinski DA, Tofler GH, Muller JE et al. Morning increase in platelet aggregability. Association with upright posture. Circulation 1988; 78: 35-40.
    CrossrefPubMedGoogle Scholar
  • 6 Ridker PM, Manson JE, Buring JE et al. Circadian variation of acute myocardial infarction and the effect of a low-dose aspirin in a randomised trial of physicians. Circulation 1990; 82: 897-902.
    CrossrefPubMedGoogle Scholar
  • 7 Patrono C, Patrignani P, Rocca B et al. Characterization of biochemical and functional effects of antiplatelet drugs as a key to their clinical development. Thromb Haemost 1995; 74: 396-400.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Pradelles P, Grassi J, Maclouf J. Enzyme immunoassay of eicosanoids using acetylcholine esterase as label: an alternative to radioimmunoassay. Anal Chem 1985; 57: 1170-3.
    CrossrefPubMedGoogle Scholar
  • 9 Lellouch F, Fradin A, Fitzgerald GA. et al. Enzyme immunoassay measurement of the urinary metabolites of thromboxane A2 and prostacyclin. Prostaglandins 1990; 40: 297-310.
    CrossrefPubMedGoogle Scholar
  • 10 Davì G, Gresele P, Violi F et al. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Circulation 1997; 96: 69-75.
    CrossrefPubMedGoogle Scholar
  • 11 Tohgi H, Konno S, Tamura K et al. Effects of lowto- high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. Stroke 1992; 23: 1400-3.
    CrossrefPubMedGoogle Scholar
  • 12 Montalescot G, MacLouf J, Drobinski G et al. Eicosanoid biosynthesis in patients with stable angina: beneficial effects of very low dose aspirin. J Am Coll Cardiol 1994; 24: 33-8.
    CrossrefPubMedGoogle Scholar
  • 13 Belton O, Byrne D, Kearney D et al. Cyclooxygenase- 1 and –2 dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102: 840-5.
    CrossrefPubMedGoogle Scholar
  • 14 Kearney D, Byrne A, Crean P et al. Optimal suppression of thromboxane A2 formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor. J Am Coll Cardiol 2004; 43: 526-31.
    CrossrefPubMedGoogle Scholar